The incremental value of aspartate aminotransferase/alanine aminotransferase ratio combined with CURB-65 in predicting treatment outcomes in hospitalized adult community-acquired pneumonia patients with type 2 diabetes mellitus

Table 2 Predictive ability of laboratory indices for forecasting treatment outcome for CAP-T2DM patients

Variables	AUC	Cut-off value	Youden index	Sensitivity	Specificity	PPV	NPV
AST/ALT	0.676 (0.575–0.776)	1.625	0.336	0.500	0.836	0.476	0.848
WBC	0.647 (0.549–0.745)	10.700	0.289	0.585	0.704	0.375	0.848
CK	0.635 (0.523–0.747)	81.000	0.255	0.688	0.568	0.386	0.821
LYM	0.594 (0.487–0.700)	0.863	0.272	0.561	0.711	0.371	0.842
PLR	0.579 (0.467–0.691)	191.821	0.276	0.634	0.642	0.351	0.851
ADA	0.577 (0.470–0.684)	18.550	0.200	0.500	0.700	0.339	0.820
GGT	0.564 (0.443–0.684)	28.000	0.154	0.750	0.404	0.300	0.826
APTT	0.557 (0.452–0.663)	33.150	0.164	0.500	0.664	0.323	0.806
GLU	0.556 (0.445–0.668)	9.980	0.159	0.647	0.512	0.268	0.840
5’-NT	0.533 (0.426–0.640)	13.100	0.121	0.275	0.846	0.355	0.791
CHE	0.520 (0.400–0.639)	8109.500	0.118	0.281	0.837	0.375	0.770
K	0.519 (0.412–0.625)	4.045	0.107	0.463	0.644	0.288	0.794
ALP	0.518 (0.389–0.647)	136.500	0.205	0.344	0.862	0.458	0.794

CAP-T2DM community-acquired pneumonia with type 2 diabetes mellitus, AUC area under the receiver operating characteristic curve, PPV positive predictive value, NPV negative predictive value, AST/ALT aspartate aminotransferase/alanine aminotransferase ratio, WBC white blood cell, CK creatine kinase, LYM lymphocyte, PLR platelet-lymphocyte ratio, ADA adenosine deaminase, GGT γ-glutamyltransferase, APTT activated partial thromboplastin time, GLU glucose, 5’-NT 5-nucleotidase, CHE acetylcholine esterase, K potassium, ALP alkaline phosphatase

ISSN: 1471-2466